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Background: Anorexia nervosa (AN) is associated with a high mortality rate. This study describes a compulsory
re-feeding program established in Munich for extremely underweight patients.
Methods: The contract between the patient and the therapeutic team included mandatory inpatient status,
establishment of guardianship and compulsory re-feeding with a percutaneous gastric feeding tube, as indicated.
The predefined target was a body mass index (BMI) of 17 kg/m2. Data on the first 68 patients with AN are presented.
Results: 65 (95.6%) patients were female and mean age at admission was 26.5 ± 8.5 years. BMI increased from 12.3 ±
1.4 kg/m2 at admission to 16.7 ± 1.7 kg/m2 at discharge. Thirty-two (47.1%) patients had the restrictive subtype (ANR)
and 36 (52.9%) had the binging and purging subtype (ANBP). Duration of illness before admission (p = .004), days of
treatment until discharge (p = .001) and weight increase (p = .02) were significantly different between subgroups in
favor of patients with ANR. Also, seasonal differences could be found. Comparison of feeding methods showed that
percutaneous tube feeding was superior. Almost half of the patients were treated with psychotropic medication. To
date, however, the number of patients included in this program is too small to assess rare complications of this acute
treatment program and long term outcomes of AN.
Conclusions: An intensive care program for severely ill AN patients has been successfully established. Besides averting
physical harm in the short term, this program was designed to enable these patients to participate in more
sophisticated psychotherapeutic programs afterwards. To our knowledge, this is the first such program that regularly
uses percutaneous feeding tubes.
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Anorexia nervosa (AN) is associated with one of the high-
est mortality rates in psychiatry. For example, a Swedish
register study comparing observed with expected death
rates reported that people hospitalized for AN had a stan-
dardized mortality rate of 6.2 [1], and a follow-up study of
51 patients hospitalized for AN found that only half were
symptom-free after 18 years [2]. Although the incidence of
AN has been reported to have increased in the last few* Correspondence: christoph.born@med.uni-muenchen.de
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unless otherwise stated.decades [3], others have reported that this perception is
incorrect, with apparent increases being due to complex
interrelations among age, observational period, and cohort
effects [4,5]. However, an epidemiological study in adoles-
cents found symptoms of eating disorders in 24% of girls
and 16% of boys [6].
Epidemiological assessments of morbidity and mortality
have shown that AN is one of the most serious disorders
in psychiatry [7]. Its psychiatric and somatic co-morbidities
indicate that AN is complex and difficult to treat. Many
co-morbid psychiatric disorders have been detected in
patients with eating disorders. For example, the lifetime
prevalence rates of mood disorders were estimated to
be as high as 75% in patients with eating disorders, andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Born et al. BMC Psychiatry  (2015) 15:57 Page 2 of 7the co-morbidity rates of obsessive-compulsive dis-
order, anxiety disorders and substance abuse to be 40%,
11–20%, and 40%, respectively [8]. Adolescents with an
affective disorder were reported to be at higher risk of
developing an eating disorder [9]. Personality traits
often found in patients with AN include perfectionism,
impulsivity and obsessive-compulsive characteristics.
Obsessive-compulsive personality disorder is the most
common personality disorder in patients with restrict-
ive AN (ANR), whereas borderline personality disorder
is the most prominent in patients with the binging and
purging subtype of AN (ANBP) [10].
Malnutrition and long-time starvation affect almost
every organ in the body [11]. Cardiac complications are
observed in about 80% of these patients; one of the most
threatening consequences is atrophy of the heart, leading
to alterations in cardiac electrical activity, structure and
hemodynamics. Atrophy may result in secondary pro-
longation of the QT-interval and cardiac arrhythmia,
complications predictive of sudden cardiac death [12].
Reduced concentrations of sodium and potassium con-
tribute not only to cardiac arrhythmia, but may lead to
myelinolysis of the pons [13]. Serum concentrations of
phosphate and magnesium are often diminished during
enforced refeeding, which may contribute to the develop-
ment of a ‘refeeding syndrome’ [14,15]. The most frequent
endocrine dysfunction associated with AN is amenorrhea
[16], although chronic starvation may induce type 1 dia-
betes mellitus [17].
Due to the potentially lethal impact of AN on physical
health, and studies showing that weight restoration sig-
nificantly ameliorated several neuropsychological aspects
of AN [18,19] and reduced EEG abnormalities [20], the
first goal of AN treatment should be restoration of
weight. A detailed program for compulsory re-feeding of
patients with severe AN has therefore been established
over the last decade at the Department of Psychiatry,
University Hospital of Munich. This report describes the
demographic characteristics and short term outcomes of
the first 68 AN patients enrolled in this program.Methods
This study investigated a subsample of approximately
100 patients with AN and severe underweight who had
been admitted to our hospital between 2000 and 2013.
Some patients were admitted two or three times because
of relapse. All patients included in this analysis were ad-
mitted for the first time to our psychiatric intensive care
unit (PICU) and were treated according to the formal-
ized re-feeding program. The local ethics board of the
Ludwig Maximilians-University consented to this evalu-
ation of prospectively collected, routine clinical data for
scientific purposes.The re-feeding program had been developed especially
for patients with AN and extreme underweight, as de-
scribed [21]. Of the 68 included patients, 51 (75%) had a
body mass index (BMI) under 13 kg/m2 at admission.
Based on British (NICE, Eating Disorders, Clinical guide-
lines no. 9, 2004, www.nice.org.uk [22]) and German
(Diagnostik und Therapie der Essstörungen, S3-Leitlinie
der AWMF, 2010, www.awmf.org [23]) guidelines for the
inpatient treatment of AN, the primary aim of the refeed-
ing program was to attain a BMI of 17 kg/m2 by gaining
700–1000 g per week. Cornerstones of the program in-
clude legal guardianship, acceptance of a percutaneous
gastric feeding tube if not contraindicated for medical rea-
sons, and a detailed contract between the patient and the
therapeutic team; this contract couples steps of weight
gain with leave from the ward, reduction of feeding with
high caloric nutrients and participation in additional
therapeutic programs and psychotherapy.
Legal guardianship of these patients was established
according to Bavarian state law. If the responsible med-
ical officer decided that a patient admitted to hospital
lacks the insight or capacity to make informed decisions
on medical treatment and need for hospitalization to
avoid acute harm to self or others, that officer could
apply for sectioning and the granting of legal guardian-
ship at a local court. A section and legal guardianship
had been established in almost all of our patients before
or at the time of admission. The section consisted of the
right to administer compulsory treatment, including
enforced feeding if necessary, and inpatient status with
restrictions of free movement for a fixed time period.
Besides offering all patients regular meals, they were
advised to undergo insertion of a percutaneous gastric
feeding tube, unless there were medical contraindica-
tions. Based on treatment targets, most patients had to
gain approximately 10 kg of body weight to reach 90%
of the ideal body weight within an acceptable time
frame. Feeding with a percutaneous gastric tube was
chosen for several reasons. First, additional feeding using
a tube was likely to be necessary for several months. In
contrast, prolonged use of a nasogastric tube can cause
damage to the nose or upper gastrointestinal tract and
the tube has to be changed regularly. Second, patients
are more handicapped when consuming food orally.
Third, patients were more likely to manipulate or remove
a nasogastric than a percutaneous gastric tube. Finally,
a nasogastric tube can be stigmatizing in a PICU environ-
ment, which also admits patients with other psychiatric
disorders.
The contract between the patient and the treatment
team was regarded as a basic tool of behavioral therapy
to motivate the patient. This contract included rules of
behavior, types of therapy being offered, rewards and
restrictions.
Table 1 Demographic and clinical characteristics of
patients with ANR and ANBP
ANR ANBP P
Patients (n) 32 (47.1%) 36 (52.9%)
Female (n) 29 (90.6%) 36 (100%)
Age (years) 25.6 ± 10.0 27.3 ± 7.0 p = .4*
Duration of illness (years) 7.0 ± 5.7 11.6 ± 7.1 p = .004*
Days of treatment 118.0 ± 57.2 178.9 ± 88.4 p = .001*
BMI at admission 11.9 ± 1.4 12.6 ± 1.3 p = .06*
BMI at discharge 16.9 ± 1.6 16.4 ± 1.8 p = .3*
Weight increase (kg) 13.5 ± 3,7 10.7 ± 5.7 p = .02*
Medication at discharge (n) 17 (53.1%) 23 (63.9%) p = .09**
Antidepressants 16 (50%) 21 (58.3%) p = .15**
Antipsychotics 6 (18.8%) 9 (25%) p = .1**
Anticonvulsants 0 (0%) 3 (8.3%) -
L-thyroxine 3 (9.4%) 6 (16.6%) p = .4**
*t test, **chi square test.
Abbreviations: ANR Anorexia nervosa, restrictive subtype, ANBP Anorexia
nervosa, binging/purging subtype.
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offered only upon demand and only for management of
an acute crisis. Regular psychotherapeutic sessions were
offered when patients reached a BMI of approximately
15 kg/m2 and were considered able to participate in
regular sessions of 50 minutes each. Participation in
therapeutic programs should not interfere with the pri-
mary aim of gaining body weight. Moreover, most
underweight patients feel restless owing to their mental
and physical condition, with this restlessness making
participation in psychotherapeutic sessions problematic.
All AN patients were required to participate in common
dining on the ward. Feeding with a high caloric solution
was considered an additional substitute treatment, as most
of these patients were unable to finish their regular meals
because of compensatory distracting behaviors, overvalued
ideas, gastrointestinal discomfort, and other reasons.
Following implantation of a feeding tube, a high caloric
solution was titrated individually, to a maximum of
3000 kcal per day. In the following weeks the amount
of the high caloric solution was adjusted, targeting a
weight gain of 700–1000 g per week. If necessary, pa-
tients could be treated with psychotropic medications
to target psychiatric syndromes such as depression and
lack of weight gain. Vitamins, electrolytes, and other
nutrients were administered to compensate for current
deficits.
The program mandated that high caloric solution be
stopped after patients reached a BMI of approximately
17 kg/m2, and that the feeding tube be removed if body
weight remained stable for 2 weeks. Future therapy was
planned, on an in- or outpatient basis, with most pa-
tients selecting eating disorder specific psychotherapy at
a specialized hospital. Most of these patients had been
referred from these hospitals to our PICU when they
were extremely underweight.
Weight gain was analyzed in the intention-to-treat (ITT)
population using the last observation carried forward
(LOCF) method. Categorical variables were reported as
frequencies and compared using the chi-square test,
and continuous variables were reported as mean ±
standard deviation (SD) and compared using t tests.
Comparisons of patients before and after treatment
were assessed using paired t tests.
Results
The analysis includes 68 consecutively admitted patients
who were treated for the first time for AN on our ward
and agreed to participate in the program. Of these, 65
(95.6%) were female and 3 (4.4%) were male; 32 (47.1%)
were diagnosed with ANR and 36 (52.9%) with ANBP.
Interestingly, all three male patients were diagnosed with
ANR. At admission the mean age of the 68 patients was
26.5 years (SD 8.5 years; range 16–61 years) and theirmean duration of AN was 9.5 years (SD 6.8 years; range
1–33 years). Mean treatment in the PICU was 150.2 days
(SD 80.8 days; range 56–348 days). Mean BMI was
12.3 kg/m2 (SD 1.4 kg/m2; range 8.8–14.9 kg/m2) at admis-
sion and 16.7 kg/m2 (SD 1.7 kg/m2; range 11–21.2 kg/m2)
at discharge. Mean weight increase was 12.0 kg (SD 5.1 kg;
range −0.2–20.3 kg).
Following admission, 57 (83.8%) patients underwent
implantation of a percutaneous gastric feeding tube,
three (4.4%) underwent implantation of a nasogastric
tube and eight (11.8%) received no feeding tube because
of contraindications (e.g., ascites). Thirty-four (50%)
patients were referred from psychotherapeutic in- or
outpatient settings, from which they did not benefit because
of overvalued ideas, delusions or extensive compensatory
behavior.
A comparison of the demographic characteristics and
treatment outcomes of patients in the ANR and ANBP
subgroups showed that duration of illness until admis-
sion to our hospital (p = .005) and days of treatment
until discharge from our specialized unit (p = .001) were
significantly shorter and total weight gain significantly
higher (p = .02) in the ANR than in the ANBP subgroup
(Table 1).
A comparison of the course of weight gain in the two
subgroups over the first 20 weeks after admission
showed that the kinetics of weight gain were higher in
the ANR subgroup, suggesting that binging and purging
in the ANBP group may have suppressed weight gain
(Figure 1).
Seasonal differences in BMI at admission were compared
in patients in the ANR and ANBP subgroups admitted
Figure 1 Course of weight gain (kg/week) in the ANR and ANBP diagnostic subgroups during the 20 weeks after admission. Abbreviations:
ANR, anorexia nervosa, restrictive subtype; ANBP, anorexia nervosa, binging/purging subtype.
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spring and summer. More total patients (57.3% vs. 42.7%),
as well as patients in the ANR (59.4% vs. 40.6%) and ANBP
(55.6% vs. 44.4%) subgroups, were admitted during autumn
and winter than during spring and summer. A comparison
of ANR and ANBP patients admitted during autumn and
winter showed that mean BMI (11.8 ± 1.6 kg/m2 vs. 12.8 ±
1.3 kg/m2; p = .04) and days of treatment until discharge
(120.6 ± 54.3 days vs. 191.2 ± 84.5 days; p = .003) were sig-
nificantly lower in the ANR than in the ANBP subgroup,
whereas there were no differences in mean BMI and days
of treatment between ANR and ANBP patients admitted
during spring and summer (p > .1 each).
A comparison of the 57 patients with and the 11 without
a percutaneous feeding tube showed that mean durationFigure 2 Course of weight gain over 20 weeks in groups of patients wof treatment was significantly longer in patients with
percutaneous feeding tubes (p < .01). However, patients
without a percutaneous feeding tube were younger
(mean age 22.9 ± 6.1 vs. 27.2 ± 8.8 years), had a shorter
mean duration of illness (7.3 ± 5.5 vs. 9.9 ± 7.0 years)
and a slightly higher mean BMI (12.7 ± 1.3 vs. 12.2 ±
1.4 kg/m2) at admission, and lower mean total weight
gain (11.3 ± 4.7 vs. 12.2 ± 5.2 kg, n.s.) than patients with
percutaneous feeding tubes. Figure 2 illustrates the
course of weight gain over 20 weeks in patients with
and without percutaneous gastric feeding tubes.
Examination of blood chemistry in these patients at
admission and before discharge showed no significant
changes in red and white blood cell counts, and in so-
dium and potassium concentrations (Table 2). Bloodith and without percutaneous feeding tubes (PEG).






Leucopenia (<4.0 G/l) 26 (38.2%) 19 (27.9%)
Anemia (RBC, Hb, Hc below
normal range)
19 (27.9%) 18 (26.5%)
Hyponatremia (<135 mmol/l) 18 (26.5%) 10 (14.7%)
Hypokalemia (<3.5 mmol/l) 19 (27.9%) 12 (17.7%)
ECG 1st ECG (n = 43) Last ECG (n = 43)
Days after admission 5.1 ± 6.4 124.8 ± 86.4
Bradycardia (<50 BPM) 8 (18.4%) 3 (7.0%)
Tachycardia (>100 BPM) 2 (4.7%) 4 (9.3%)
BPM (mean ± SD) 61.1 ± 17.0 73.7 ± 15.9
Abbreviations: G/l 109 cells per liter, RBC red blood cells, Hb hemoglobin,
Hc hematocrit, BPM beats per minute, SD standard deviation.
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ANR and ANBP subgroups (data not shown).
Of the 68 patients, 43 (63.2%) underwent ECG during
the first 25 days (mean 5.1 ± 6.4 days) after admission.
ECGs showed bradycardia, defined as a heart rate < 50/
min, in eight patients (18.4%) and tachycardia, defined as a
heart rate ≥100/min, in two (4.7%). ECGs performed before
discharge in these patients, at a mean 124.8 ± 86.4 days
after admission, showed bradycardia in three patients
(7.0%) and tachycardia in four (9.3%). Mean heart rate in-
creased significantly, from 61.1 ± 17.0 bpm to 73.7 ±
15.9 bpm (two sided t test; p < .001).
Of the 52 patients (76.5%) who underwent cerebral
MRI, three (5.8%) had central pontine myelinolysis and
one (1.9%) had signs of brain atrophy. Bone density was
measured at the lumbar part of the vertebral column and
the femur in 27 patients (39.7%). Of these, 19 (70.4%) had
osteoporosis, with mean femoral and lumbar mineral
contents of 0.75 ± 0.16 g/cm2 and 0.86 ± 0.16 g/m2, re-
spectively; and eight (29.6%) had osteopenia, with mean
femoral and lumbar mineral contents of 0.81 ± 0.18 g/cm2
and lumbar 0.91 ± 0.11 g/cm2, respectively. Only one
patient (3.7%) had a normal mineral content.
Psychotropic medication was offered to patients with
any comorbid psychiatric illness requiring treatment,
such as depression, generalized anxiety, or obsessive-
compulsive disorder, but not with the intention to affect
weight. Almost two thirds of these patients were being
treated with psychotropic medication at the time of dis-
charge (Table 1). Thirty-seven patients (54.4%) received
various antidepressants as monotherapy (imipramine,
trimipramine, citalopram, escitalopram, fluoxetine,
paroxetine, sertraline, mirtazapine, reboxetine or ven-
lafaxine), and five (7.4%) received a combination of
two antidepressants (SSRI +mirtazapine). Fifteen patients
(22.1%) received antipsychotics (clozapine, olanzapine,perazine, quetiapine, risperidone or zotepine). Additionally,
all 68 patients were being treated with vitamins or other
nutritional substitutes. No significant differences in medi-
cation use were observed between the ANR and ANBP
subgroups.
Patients who attained a BMI of approximately 17 kg/m2
were actively encouraged to arrange for further therapy.
Patients with ANBP were more likely to seek further
treatment in a psychiatric or psychotherapeutic hospital
(n = 30; 83.3%) than patients with ANR (n = 18; 56.3%),
whereas patients with ANR more often favored further
treatment in an outpatient setting (37.5% vs. 13.9%).Discussion and conclusions
Treatment settings and offers for people with AN and
extreme underweight (BMI <13 kg/m2) are scarce. The
described detailed treatment protocol in a PICU setting
is potentially lifesaving for these patients. To our know-
ledge, this is the only program that routinely includes
the use of a percutaneous gastric feeding tube, empha-
sizing the severity of AN and its resistance to treatment.
Most of the included patients were referred from psy-
chotherapeutic settings after failure of less restrictive
approaches.
The results reported in this article indicate that patients
with severe AN can be successfully treated, at least by re-
versing a life threatening condition. Clearly, this does not
necessarily mean a lasting change of mind set in these pa-
tients. At admission, most of the patients had a BMI under
13 kg/m2, achieving a BMI of 16 to 17 kg/m2 at discharge.
Weight gain was easier to achieve in patients with ANR.
However, patients with ANBP had a significantly longer
mean duration of illness (11.1 vs. 6.3 years; p < .004),
which may indicate a more severe and chronic course of
illness.
Differences in BMI at admission and days of treatment
in subgroups of patients with ANR and ANBP were found
to be seasonal because more patients were admitted dur-
ing autumn and winter than during spring and summer
[24]. We also found that BMI at admission (p = .04) and
days of treatment until discharge (p = .003) differed signifi-
cantly in patients with ANR and ANBP admitted during
autumn and winter (p = .04), but not during spring and
summer (p > .1 each).
The results of comparisons of patients with and without
percutaneous gastric feeding tubes must be interpreted
with caution because of the small sample size of the latter.
We found that weight gain was slightly higher in patients
with a percutaneous tube. Moreover, slight but not sig-
nificant differences from admission to discharge were
observed in the blood chemistry of patients with percu-
taneous tubes. This may have been due to unchanged
compensatory behavior (e.g. vomiting) or hormonal
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to re-feeding.
This study had several limitations, including its retro-
spective design and the uncontrolled, naturalistic nature
of the results. Patients were not randomized to treatment
regimens. The retrospective design explains missing data
for ECG, MRI and measurements of bone mineral density,
as those examinations were not part of a prospective study
protocol. Of the patients that underwent bone density
measures, 93.7% were diagnosed with osteoporosis or
osteopenia, indicating the severe physical sequelae of AN
in our patients.
Different strategies are used to treat patients with AN.
Disorder specific psychotherapy is considered first line
treatment [25,26]. Pharmacotherapy trials designed to
increase appetite and ameliorate the constricted and ob-
sessive thinking in AN, including those with olanzapine
or quetiapine, have yielded inconsistent results [27,28].
A recent meta-analysis showed that weight gain was sig-
nificantly affected by hormonal therapy, but not by treat-
ment with antidepressants or antipsychotics, compared
with placebo [29]. Finally, use of a feeding tube and high
caloric solution, may be the only successful lifesaving
treatment strategy for the most severely undernourished
patients with AN.
A Medline search using the terms “eating disorders”,
“anorexia nervosa” and “refeeding” identified eight articles
published in the last decade. Most were retrospective ana-
lyses of the outcomes of refeeding programs for patients
with AN [30-36], with outcomes defined as recovery and
complication rates. Only one prospective, randomized
study compared oral and nasogastric administration of a
high caloric solution [37]. In six studies, use of a nasogas-
tric tube was compared with oral refeeding, one compared
oral refeeding with a high caloric solution versus oral
refeeding with normal food [33], and one compared paren-
teral and oral refeeding [30]. Two of these studies included
only adolescent patients [30,35], and the duration of
refeeding varied considerably, from 15.6 days [30] to 12.3 ±
1.9 weeks [33]. In addition, body weights at baseline and
endpoint varied widely. In three studies, body weights at
start and after refeeding were comparable to those in our
patients [33,34,37]. These three studies included only adult
patients, but the observation period varied from 56 days
[37] to 12.3 ± 1.9 weeks [33]. Only one of these studies in-
cluded a standardized follow-up at 3 and 12 months after
discharge, with the time to recovery significantly longer in
the group using nasogastric feeding tubes (p < .05) [37]. An-
other study reported that, after reaching a mean BMI of
13.5 ± 1 kg/m2, 29 patients continued therapy in an out-
patient setting, finally achieving a mean BMI of 18.4 ±
2.3 kg/m2, but the duration of follow-up was not reported
[33]. Although the methods and results of these studies
were quite heterogeneous, all found that administration ofa high caloric solution using a feeding tube was superior to
oral refeeding.
Little is known about long term outcomes after refeed-
ing programs. A mean 13.5-year follow-up of 484 adult
patients with AN found that 60.3% had fully recovered,
25.8% had what was described as a good outcome, 6.4% a
bad outcome, 6.4% had a severe outcome, and 1.2% had
died [38]. Binge-eating/purging subtype and personality
disorder were identified as predictors of an inferior out-
come [38]. A comparison of 6-year outcomes in 41 se-
verely malnourished AN patients (mean BMI at admission
10.1 ± 0.57 kg/m2), started immediately on tube-refeeding,
and 443 less malnourished AN patients reported death
rates of 7% and 1.2%, respectively; severe outcome rates of
29% and 10%, respectively; and recovery rates of 41% and
62%, respectively. This indicated that prudent tube refeed-
ing, especially in AN patients with a BMI <11 kg/m2,
could reduce short-term mortality rates, although long-
term prognosis remains poor [39]. Although long term
data are not available for our cohort, only seven (10.3%)
were readmitted for re-feeding.
The program described in this article was established
for the most severely affected AN patients who are at
risk of death or irreversible physical damage [21]. As
normalization of body weight can also restore cognitive
function [19,40], these patients may be able to participate
more successfully in psychotherapeutic programs.
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